Sterling Capital Management LLC Sells 3,843 Shares of AbbVie Inc. $ABBV

Posted by Stanley Muller on Jun 28th, 2026

Sterling Capital Management LLC lessened its holdings in AbbVie Inc. (NYSE:ABBV – Free Report) by 1.4% during the first quarter, Holdings Channel.com reports. The firm owned 271,898 shares of the company’s stock after selling 3,843 shares during the quarter. AbbVie accounts for 1.1% of Sterling Capital Management LLC’s investment portfolio, making the stock its 14th largest holding. Sterling Capital Management LLC’s holdings in AbbVie were worth $59,135,000 as of its most recent SEC filing.

Several other hedge funds have also added to or reduced their stakes in the business. Chelsea Counsel Co. bought a new position in shares of AbbVie during the third quarter valued at about $26,000. Litman Gregory Wealth Management LLC bought a new stake in shares of AbbVie in the 4th quarter valued at about $28,000. Westend Capital Management LLC purchased a new stake in AbbVie during the 4th quarter valued at about $29,000. Imprint Wealth LLC boosted its holdings in AbbVie by 56.2% during the 4th quarter. Imprint Wealth LLC now owns 125 shares of the company’s stock valued at $29,000 after acquiring an additional 45 shares during the period. Finally, Texas Capital Bancshares Inc TX bought a new position in AbbVie during the 3rd quarter worth approximately $31,000. 70.23% of the stock is owned by institutional investors.

AbbVie News Summary

Here are the key news stories impacting AbbVie this week:

Positive Sentiment: AbbVie said the FDA approved Skyrizi for pediatric use in psoriatic disease, making it the first and only IL-23 inhibitor in the U.S. approved for children six years and older weighing less than 40 kg with plaque psoriasis or psoriatic arthritis. The expansion broadens the drug’s addressable market and supports long-term sales growth. Article: SKYRIZI® (risankizumab-rzaa) Now FDA Approved for Pediatric Use in Psoriatic Disease
Positive Sentiment: AbbVie’s Apogee Therapeutics acquisition is being viewed favorably by analysts, with Canaccord raising its price target and saying the deal strengthens AbbVie’s long-term growth outlook by adding promising pipeline assets. Article: AbbVie Just Sparked a 46% Rally in Apogee. Here’s Why This $10.9 Billion Deal Could Be a Win for AbbVie Investors.
Positive Sentiment: AbbVie is also benefiting from broader healthcare sector strength, with shares hitting new highs as investors rotate into defensive large-cap pharma names. Article: Lilly, J&J, AbbVie hit all-time highs as healthcare outperforms
Neutral Sentiment: AbbVie announced it will host its second-quarter 2026 earnings call on July 31, which is a standard investor update and does not by itself change fundamentals. Article: AbbVie to Host Second-Quarter 2026 Earnings Conference Call
Neutral Sentiment: Commentary pieces also highlighted AbbVie’s recent pediatric label expansions in Europe for Skyrizi and Maviret, reinforcing the company’s shift toward earlier-disease and younger-patient growth opportunities. Article: Will AbbVie’s (ABBV) Pediatric Expansions Reveal a Deeper Shift in Its Growth Mix?

AbbVie Stock Performance

NYSE ABBV opened at $251.52 on Friday. AbbVie Inc. has a fifty-two week low of $181.73 and a fifty-two week high of $253.35. The stock has a 50 day simple moving average of $215.16 and a two-hundred day simple moving average of $219.18. The stock has a market cap of $444.38 billion, a P/E ratio of 123.90, a price-to-earnings-growth ratio of 0.77 and a beta of 0.32.

AbbVie (NYSE:ABBV – Get Free Report) last issued its quarterly earnings data on Wednesday, April 29th. The company reported $2.65 earnings per share for the quarter, topping analysts’ consensus estimates of $2.59 by $0.06. AbbVie had a negative return on equity of 576.45% and a net margin of 5.79%.The firm had revenue of $15 billion for the quarter, compared to analyst estimates of $14.72 billion. During the same period last year, the company earned $2.46 EPS. The business’s quarterly revenue was up 12.4% compared to the same quarter last year. Sell-side analysts predict that AbbVie Inc. will post 14.28 earnings per share for the current year.

AbbVie Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, August 14th. Investors of record on Wednesday, July 15th will be issued a $1.73 dividend. The ex-dividend date is Wednesday, July 15th. This represents a $6.92 annualized dividend and a yield of 2.8%. AbbVie’s payout ratio is 340.89%.

Wall Street Analyst Weigh In

ABBV has been the subject of several recent research reports. Sanford C. Bernstein reiterated a “market perform” rating on shares of AbbVie in a research report on Tuesday. Wells Fargo & Company set a $260.00 target price on shares of AbbVie in a research note on Monday, June 22nd. Evercore set a $235.00 price target on shares of AbbVie in a report on Friday, May 15th. William Blair reissued an “outperform” rating on shares of AbbVie in a research report on Monday, March 9th. Finally, Canaccord Genuity Group raised their price target on shares of AbbVie from $265.00 to $273.00 and gave the stock a “buy” rating in a report on Tuesday. Three investment analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat.com, AbbVie has a consensus rating of “Moderate Buy” and an average price target of $253.81.

View Our Latest Report on AbbVie

AbbVie Company Profile

(Free Report)

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.